FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIALR. Gressin,Nicolas Daguindau, Adrien Tempescul,Anne Moreau,Sylvain Carras,G. Cartron, A. Schmitt,Roch Houot,Caroline Dartigeas,Jean-Michel Pignon,Selim Corm, A. Bannos,Christiane Mounier,Jehan Dupuis, Margareth Macro,Joel Fleury, Fabrice Jardin,Lionel Karlin,Ghandi Damaj,P. Feugier,Luc-Matthieu Fornecker,Cécile Chabrot, I. Ysebaert,Mary Callanan,S. Le GouillHematological Oncology（2017）引用 3|浏览68暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
